CAPITALSTARS PRESENTS EQUITY MARKET UPDATE : 27 JAN 2020

INDIAN FACE  

                      

INDIAN EQUITY BENCHMARK

The benchmark S&P BSE Sensex plunged 458.07 points, or 1.10 per cent, to settle at 41,155.12 level. Apart from Tata Steel, IndusInd Bank, HDFC Bank, and State Bank of India were the top laggards. In the intra-day trade, the index tanked 490 points to hit a low of 41,122.48.

GLOBAL FACE

Asian Market- Nikkei falls as coronavirus fears rise; most Asian markets remain closed for holiday. The Nikkei NIK, -2.03% was last down 1.8%. Shares of Pacific Metals 5541, -7.90% and Fast Retailing 9983, -5.66% sank, along with Softbank 9984, -4.13% and Toyota 7203, - 1.52%.

U.S. Market – U.S. stock futures tumble as China coronavirus spreads, worries escalate. U.S. stock futures indicated sharp losses for major indexes on Monday, continuing a drop seen from late last week, as concern grows over the fallout from China’s coronavirus, with the death toll and number of infected climbing dramatically from last week.

European markets- European stocks fall sharply as China virus fears intensify; Stoxx 600 down 1.4%.European stocks tumbled on Monday as fears over the economic fallout from the Chinese coronavirus outbreak intensify.

NIFTY SPOT

MARKET TALKS

Interglobe Aviation posts 167% yoy rise in net profit for Q3FY20

Interglobe Aviation's revenue from operations stood at Rs9, 931.7cr for the quarter, an increase of 25.5% against a 19.3% increase in capacity compared to same period last year. EBITDA came in at Rs1,960cr compared to EBITDA of Rs1,672.9cr for the same period.Profit Before Tax stood at Rs556.5cr and PAT of Rs496cr for Q3FY20 (a rise of 168% yoy). Basic earnings per share was at Rs12.89 for the quarter.

BSE signs licensing agreement with ICE Futures Europe

BSE India’s leading exchange, has signed a licensing agreement with Intercontinental Exchange, Inc, a leading operator of global exchanges and clearing houses and provider of data and listings services, for the use of the ICE Brent Index as the final settlement price for BSE’s rupee-denominated Brent futures contract.

Wockhardt posts net profit at Rs9cr in Q3FY20

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported a consolidated net profit of Rs9cr in Q3FY20 as against a net loss of Rs71cr. The company’s revenue came in at Rs869.2cr vs. Rs1, 045.7cr. The business performance of the Company during the quarter ended December 31, 2019, showed a marked improvement with sales growth of over 8% compared to the previous quarter. EBITDA for the quarter showed a substantial improvement from Rs19cr in Q3FY19 to Rs109cr in Q3FY20.

Dr. Reddy's Laboratories posts net loss at Rs569.7cr

Dr. Reddy's Laboratories Ltd registered a consolidated net loss of Rs569.7cr in Q3FY20 vs. a net profit of Rs485.2cr. Its revenue rose 13.8% yoy to Rs4,384cr in Q3FY20. Q3FY20 financials include an impairment charge of Rs1,320cr on some of the company's products forming part of Global Generics and Proprietary Products segments, the pharma company said in the filing.

NAME OF THE STOCK : DR REDDY

DATE : 27/1/2020

SEGMENT : CASH 

CHART TYPE : Candlestick

EXCHANGE : NSE 

INVESTMENT ADVICE: CS CALL - BUY PEL IN CASH NR CMP 1685-1690 TGT 1740 SL 1645

RATIONALE FOR ARRIVING INVESTMENT ADVICE : We Provide Trading calls on the basis of following key points: 

1. Technical Analysis (Use of Candlestick Charts, Technical Indicators like: RSI, MACD, Stochastic, ADX etc,) 

2. Fundamentals of the Company 

3. Live Market News & Updates (Company related, Sector related, Economy related, political, Global news etc.) 

4. Tracking of Market Data’s (GDP, IIP, CPI, WPI, TRADE BALANCE etc.) 

5. Tracking of Market Events like (RBI POLICY, FED POLICY, ECB MEETING, and OPEC MEETING etc.) 

6. Tracking of Market Trends like Bullish Trend, Bearish Trend, and Consolidation etc.

DISCLAIMER

The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and upon sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as the only factor while making investment decisions. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. CapitalStars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets is always subjected to market risk.

CLICK HERE FOR GETTING DETAILS & JOIN OUR BEST ADVISORY  -

Visit our Link : https://www.capitalstars.com/free-trial

Visit My Website: https://www.capitalstars.com/

CAPITALSTARS CALL US : 9977499927

Derivatives Tips , Intraday Stock Tips , FreeTrading Tips, Sebi Registered advisory